493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors

• Homer Adams,
• Patricia LoRusso,
• Juanita Lopez,
• Melissa Johnson,
• Özlem Türeci,
• Tahamtan Ahmadi,
• Ugur Sahin,
• Jessica Bauman,
• Daniel Haggstrom,
• Eleni Lagkadinou,
• Gaurav Bajaj,
• Yali Fu,
• Kristoffer Rohrberg

Affiliations

Homer Adams

Aff565 Janssen Pharmaceutical R&D Spring House PA USA

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

Juanita Lopez

Institute of Cancer Research, London, UK

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Özlem Türeci

1BioNTech SE, Mainz, Germany

Tahamtan Ahmadi

2Genmab A/S, Utrecht, Netherlands

Ugur Sahin

1BioNTech SE, Mainz, Germany

Jessica Bauman

7Fox Chase Cancer Center, Philadelphia, PA, USA

Daniel Haggstrom

5Levine Cancer Institute, Charlotte, NC, USA

Eleni Lagkadinou

6BioNTech SE, Mainz, Germany

Gaurav Bajaj

7Genmab, Princeton, NJ, USA

Yali Fu

7Genmab, Princeton, NJ, USA

Kristoffer Rohrberg

8Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark